MX2023001136A - Forma cristalina de clorhidrato de fentermina y proceso de obtencion de la misma. - Google Patents

Forma cristalina de clorhidrato de fentermina y proceso de obtencion de la misma.

Info

Publication number
MX2023001136A
MX2023001136A MX2023001136A MX2023001136A MX2023001136A MX 2023001136 A MX2023001136 A MX 2023001136A MX 2023001136 A MX2023001136 A MX 2023001136A MX 2023001136 A MX2023001136 A MX 2023001136A MX 2023001136 A MX2023001136 A MX 2023001136A
Authority
MX
Mexico
Prior art keywords
crystalline form
phentermine
obtaining same
phentermine hydrochloride
present
Prior art date
Application number
MX2023001136A
Other languages
English (en)
Inventor
Oliveira Faria Luiz Felipe De
Kobata Pedro Yuri Gerônimo
Original Assignee
Eurofarma Laboratorios S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurofarma Laboratorios S A filed Critical Eurofarma Laboratorios S A
Publication of MX2023001136A publication Critical patent/MX2023001136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82—Purification; Separation; Stabilisation; Use of additives
    • C07C209/86—Separation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la forma cristalina de clorhidrato de fentermina monohidratada y a procesos de obtención de la forma cristalina. Fentermina o 2-metil-1-fenilpropan-2-amina se encuentra en forma de sal de clorhidrato, siendo un estimulante del sistema nervioso central, usado como un supresor del apetito y estimulante en medicamentos. La presente invención se encuentra en los campos de la química y la farmacia.
MX2023001136A 2020-07-27 2020-07-27 Forma cristalina de clorhidrato de fentermina y proceso de obtencion de la misma. MX2023001136A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2020/050290 WO2022020910A1 (pt) 2020-07-27 2020-07-27 Forma cristalina de cloridrato de fentermina e processo de obtenção da mesma

Publications (1)

Publication Number Publication Date
MX2023001136A true MX2023001136A (es) 2023-03-21

Family

ID=79283588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001136A MX2023001136A (es) 2020-07-27 2020-07-27 Forma cristalina de clorhidrato de fentermina y proceso de obtencion de la misma.

Country Status (10)

Country Link
US (1) US20230265043A1 (es)
EP (1) EP4190320A4 (es)
AR (1) AR123045A1 (es)
BR (1) BR112023001519A2 (es)
CA (1) CA3187100A1 (es)
CO (1) CO2023000499A2 (es)
MX (1) MX2023001136A (es)
PE (1) PE20231051A1 (es)
UY (1) UY39335A (es)
WO (1) WO2022020910A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2408345A (en) * 1942-04-13 1946-09-24 Wm S Merrell Co Composition of matter and method
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
WO2009098169A1 (en) * 2008-02-05 2009-08-13 Alpex Pharma Sa Orally disintegrating tablets with speckled appearance
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
IN2012DE00826A (es) * 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN103316026B (zh) * 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法

Also Published As

Publication number Publication date
EP4190320A4 (en) 2024-05-01
CO2023000499A2 (es) 2023-03-17
US20230265043A1 (en) 2023-08-24
BR112023001519A2 (pt) 2023-02-14
UY39335A (es) 2021-11-30
EP4190320A1 (en) 2023-06-07
CA3187100A1 (en) 2022-02-03
AR123045A1 (es) 2022-10-26
WO2022020910A1 (pt) 2022-02-03
PE20231051A1 (es) 2023-07-11

Similar Documents

Publication Publication Date Title
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
CR20230230A (es) Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
BRPI0515170A (pt) processos para a produção de (s) -2- (1, 6, 7, 8- tetraidro-2h-indeno [5, 4 -b] furan -8- il) etilamina ou um sal do mesmo e para a produção de cristais de (s) -n- [2- (1, 6, 7, 8 - tetraidro -2h- indeno [5, 4 -b] furan -8- il) etil] propionamida, cristais de (s) -n- [2- (1, 6, 7, 8 -tetraidro -2h- indeno [5-4-b] furan -8- il) etil] propionamida, composição, processo para a produção de 1, 2 , 6, 7- tetraidro -8h- indeno [5, 4-b] furan -8- ona, uso dos cristais, e, método para a prevenção ou tratamento de distúrbios do sono
MX2022013974A (es) Inhibidor de sos1 que contiene fosforo.
SG10201809696UA (en) Processes and intermediates for preparing a medicament
MX2016013908A (es) Novedoso compuesto de 1,2,4-triazina disustituida.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
FI3119911T3 (fi) Yhdisteitä käytettäväksi alzheimerin taudin hoitamisessa apoe4+/+-potilaissa
MX2019014885A (es) Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido).
AU2016237099B2 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
ZA202204666B (en) 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
MX2023001136A (es) Forma cristalina de clorhidrato de fentermina y proceso de obtencion de la misma.
MX2023008923A (es) Composicion farmaceutica que comprende un derivado de difenilpirazina.
BRPI0409038A (pt) processos para preparação de um produto de reação, de uma composição farmacêutica, de uma composição agroquìmica, de uma composição de limpeza, de uma composição de tinta e de um refrigerante ou lubrificante
PH12020500462A1 (en) Use of glutarimide derivative to treat diseases related to the aberrant activity of cytokines
BR112017025135A2 (pt) processos para isolar um composto e para preparar um composto
ATE386734T1 (de) Verfahren zur herstellung von (4-hydroxy-6-oxo- tetrahydropyran-2-yl) acetonitril und dessen derivaten
GB1288205A (es)
CL2023000185A1 (es) Forma cristalina de clorhidrato de fentermina y proceso de obtención de la misma
ATE423091T1 (de) Verfahren zur synthese von l-y- methylenglutaminsäure und analoga
DE60230552D1 (de) Verbessertes verfahren zur herstellung von gabapentin
SG11201807335VA (en) Method for producing particulate ruthenium
BRPI0409039A (pt) processo para a preparação de um produto de reação, processos para a preparação de uma composição farmacêutica, agroquìmica, de limpeza e de tinta, e processo para a preparação de um refrigerante
MX2023003873A (es) Oximas de benzaldehido y metodo para su preparacion.